Literature DB >> 17300935

Structure-activity relationship studies on anti-HCV activity of ring-expanded ('fat') nucleobase analogues containing the imidazo[4,5-e][1,3]diazepine-4,8-dione ring system.

Peng Zhang1, Ning Zhang, Brent E Korba, Ramachandra S Hosmane.   

Abstract

In continuation of our structure-activity relationship studies on anti-HCV activity of the title imidazo[4,5-e][1,3]diazepine ring system, we report here the synthesis and effect on biological activity of introducing hydrophobic substituents at the 2-position of the heterocycle. Our results suggest that there is no particular advantage to that end as the observed antiviral activity of the test compounds was lower than that of the unmodified 2-bromo derivative used for comparison. The activity/toxicity profile of all target compounds, however, was still better than that of the reference compound ribavirin used in the antiviral assay, but not as good as that of interferon-alpha, the other reference compound used in the assay.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17300935      PMCID: PMC2700783          DOI: 10.1016/j.bmcl.2007.01.085

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  16 in total

1.  Antiviral amphipathic oligo- and polyribonucleotides: analogue development and biological studies.

Authors:  Robyn M Hyde; Arthur D Broom; Robert W Buckheit
Journal:  J Med Chem       Date:  2003-05-08       Impact factor: 7.446

Review 2.  Prospects for a vaccine against the hepatitis C virus.

Authors:  Michael Houghton; Sergio Abrignani
Journal:  Nature       Date:  2005-08-18       Impact factor: 49.962

3.  New perspectives for T-cell-based HCV vaccines.

Authors:  Carlo Ferrari
Journal:  J Hepatol       Date:  2006-04-27       Impact factor: 25.083

4.  Azapeptides as inhibitors of the hepatitis C virus NS3 serine protease.

Authors:  Rumin Zhang; James P Durkin; William T Windsor
Journal:  Bioorg Med Chem Lett       Date:  2002-04-08       Impact factor: 2.823

5.  Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.

Authors:  Chiaki Okuse; Jo Ann Rinaudo; Kristine Farrar; Frances Wells; Brent E Korba
Journal:  Antiviral Res       Date:  2005-01       Impact factor: 5.970

6.  Synthesis and in vitro anti-hepatitis B and C virus activities of ring-expanded ('fat') nucleobase analogues containing the imidazo[4,5-e][1,3]diazepine-4,8-dione ring system.

Authors:  Peng Zhang; Ning Zhang; Brent E Korba; Ramachandra S Hosmane
Journal:  Bioorg Med Chem Lett       Date:  2005-10-05       Impact factor: 2.823

Review 7.  Selective inhibitors of hepatitis C virus replication.

Authors:  Johan Neyts
Journal:  Antiviral Res       Date:  2006-06-23       Impact factor: 5.970

Review 8.  Challenges and successes in developing new therapies for hepatitis C.

Authors:  Raffaele De Francesco; Giovanni Migliaccio
Journal:  Nature       Date:  2005-08-18       Impact factor: 49.962

9.  Ring-expanded ("fat") nucleoside and nucleotide analogues exhibit potent in vitro activity against flaviviridae NTPases/helicases, including those of the West Nile virus, hepatitis C virus, and Japanese encephalitis virus.

Authors:  Ning Zhang; Huan-Ming Chen; Verena Koch; Herbert Schmitz; Ching-Len Liao; Maria Bretner; Vishweshwar S Bhadti; Ali I Fattom; Robert B Naso; Ramachandra S Hosmane; Peter Borowski
Journal:  J Med Chem       Date:  2003-09-11       Impact factor: 7.446

Review 10.  Recent development of therapeutics for chronic HCV infection.

Authors:  Zhuhui Huang; Michael G Murray; John A Secrist
Journal:  Antiviral Res       Date:  2006-06-23       Impact factor: 5.970

View more
  1 in total

1.  Structure-based drug design and potent anti-cancer activity of tricyclic 5:7:5-fused diimidazo[4,5-d:4',5'-f][1,3]diazepines.

Authors:  Atul Kondaskar; Shilpi Kondaskar; James C Fishbein; Brandon A Carter-Cooper; Rena G Lapidus; Mariola Sadowska; Martin J Edelman; Ramachandra S Hosmane
Journal:  Bioorg Med Chem       Date:  2012-12-11       Impact factor: 3.641

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.